Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02951195 · ClinicalTrials.gov registry record · Phase 2

A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

A Phase 2 study of Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated.

Completed
Registry status
Phase 2
Development phase
80
Enrollment target
16
Study locations

NCT02951195 is a Phase 2 study of Cystic Fibrosis that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 80 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (55% lower). The trial reports 16 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02951195, a Phase 2 study of Cystic Fibrosis, has completed, sponsored by Vertex Pharmaceuticals Incorporated.

COMPLETED
Registry status
Phase 2
Development phase
80 participants
Enrollment target
16
Study locations

Study Summary

This is a Phase 2, randomized, double blind, placebo and active-controlled, parallel group, multicenter study designed to evaluate the safety and tolerability of VX-152 in Triple Combination (TC) with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ and/or IVA therapy (F508del/MF), or who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F508del/F508del).

Conditions Studied

Cystic Fibrosis

Interventions

  • DRUG Placebo
  • DRUG IVA
  • DRUG TEZ/IVA
  • DRUG VX-152

Study Locations (16)

California

  • - La Jolla
  • - Los Angeles

Illinois

  • - Chicago
  • - Peoria

Ohio

  • - Akron
  • - Cleveland

Texas

  • - Fort Worth
  • - Houston

Alabama

  • - Birmingham

Florida

  • - Orlando

Missouri

  • - St Louis

North Carolina

  • - Chapel Hill

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2016-11
Est. Completion 2018-01
Phase Phase 2

Sponsor

Vertex Pharmaceuticals Incorporated

191 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02951195

The ClinicalTrials.gov registry entry for NCT02951195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (55% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT02951195 reports 16 study locations spanning 12 distinct geographic areas - top geographies include California, Illinois, Ohio.

Frequently Asked Questions

What is clinical trial NCT02951195 about?

NCT02951195 is a clinical study titled "A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis". This is a Phase 2, randomized, double blind, placebo and active-controlled, parallel group, multicenter study designed to evaluate the safety and tolerability of VX-152 in Triple Combination (TC) with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with cystic fibrosis (CF) who are ...

What is the current status of trial NCT02951195?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2016-11. Estimated completion is 2018-01.

What conditions does trial NCT02951195 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

What interventions are being tested in trial NCT02951195?

The interventions under investigation include: Placebo (DRUG), IVA (DRUG), TEZ/IVA (DRUG), VX-152 (DRUG).

Who is sponsoring clinical trial NCT02951195?

This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02951195 being conducted?

This trial has 16 study locations across Alabama, California, Florida, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cystic Fibrosis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.